CLINICAL TRIAL / NCT04586166

Inclusion Criteria: - At least 21 years of age - Vaginal bulge symptoms as indicated by an affirmative response of >1 to question 3 of the PFDI-SF20 - POP ≥ stage II according to the pelvic organ prolapse quantification (POP-Q) system45, with evidence of apical descent - Women being considered for minimally invasive sacrocolpopexy (with or without concomitant hysterectomy) - Objective SUI: positive standardized cough stress test on clinical examination or on urodynamic study with reduced prolapse - Understanding and acceptance of the need to return for all scheduled follow-up visits and willing to complete study questionnaires - Able to give informed consent Exclusion Criteria: - Prior surgery for stress urinary incontinence including mid-urethral sling; Burch/MMK; fascial pubovaginal sling (autologous, xenograft or allograft); and urethral bulking injection - Any serious disease, or chronic condition, that could interfere with the study compliance - Unwilling to have a synthetic sling - Untreated and unresolved urinary tract infection - Poorly-controlled diabetes mellitus (HgbA1c > 9 within 3 months of surgery date) - Neurogenic bladder/ pre-operative self-catheterization - Elevated post-void residual/PVR (>150 ml) that does not resolve with prolapse reduction testing (pessary, prolapse reduced uroflow or micturition study) - Prior pelvic radiation - Inflammatory bowel disease - Current genitourinary fistula or urethral diverticulum - Planned concomitant bowel related surgery including sphincteroplasty and perineal rectal prolapse surgery, rectovaginal fistula repair, hemorrhoidectomy - Pregnant or Planning to Conceive - Incarcerated